ALEC

NASD Alector, Inc.
Oct 7, 2026 · 2:42 PM ET DELAYED Market Open

$1.87 ↑ +0.05 (+3.04%) Trading Up from the previous close of $1.81, $0.01 below the day’s high of $1.87

YTD change
+19.55%
vs 20-day SMA
-5.38%
vs 200-day SMA
-6.63%

Price ranges

Previous day
$1.75 $2.23
open $2.10 close $1.81
-$0.29 (-13.81%)
Today
$1.73 $1.87
open $1.78 now $1.87
+$0.09 (+4.78%)
Past week
$1.75 $2.73
from $1.87 now $1.87
-$0.01 (-0.27%)
Past month
$1.75 $2.73
from $2.47 now $1.87
-$0.61 (-24.49%)
This year
$1.37 $2.76
from $1.56 now $1.87
+$0.31 (+19.55%)

Price & Performance

-0.66 (-26.72%) / 6M

$1.28$1.80$2.31$2.83Apr 7Jul 8Oct 6

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 95.7% away from all-time highs of $43.32
  • ALEC is up 20% since the beginning of the year
  • ALEC is down 39% over the past 12 months
  • ALEC is down 24% over the past 1 month
  • 6% of all ALEC investors are betting against ALEC

ALEC reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -41.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.21
Earnings momentum +1.3% Quarterly EPS growth
Quarterly change +1.3%

Valuation

P/E ratio N/A
Enterprise value $61.3M
Beta 1.56

Balance sheet & scale

IncomeN/A
Revenue$13.9M
Cash$172.8M
Debt$32.8K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $208.2M

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $402.60 -0.09%
MRNA Moderna, Inc. $187.46 -7.75%
RVMD Revolution Medicines, Inc. $199.87 -3.76%
ROIV Roivant Sciences Ltd. $35.53 -0.70%
BNTX BioNTech SE Sponsored ADR $95.73 -1.96%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.